Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382834 · ClinicalTrials.gov registry record · Phase 2
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03382834 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 31 participants.
The verdict
NCT03382834, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study evaluated the effects of tamoxifen exposure in combination with vorinostat on viral reactivation among HIV-1 infected post-menopausal women with virologic suppression on antiretroviral therapy (ART), when compared to vorinostat alone.
Interventions
- DRUG Tamoxifen
- DRUG Vorinostat
- DRUG Antiretroviral drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382834
The ClinicalTrials.gov registry entry for NCT03382834 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tamoxifen is the first listed.
NCT03382834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382834 about?
NCT03382834 is a clinical study titled "Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors". This study evaluated the effects of tamoxifen exposure in combination with vorinostat on viral reactivation among HIV-1 infected post-menopausal women with virologic suppression on antiretroviral therapy (ART), when compared to vorinostat alone.
What is the current status of trial NCT03382834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-04-26. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT03382834?
The interventions under investigation include: Tamoxifen (DRUG), Vorinostat (DRUG), Antiretroviral drugs (DRUG).
Who is sponsoring clinical trial NCT03382834?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.